Loading...

iCAD

Nasdaq:ICAD
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ICAD
Nasdaq
$127M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. The last earnings update was 65 days ago. More info.


Add to Portfolio Compare Print
  • iCAD has significant price volatility in the past 3 months.
ICAD Share Price and Events
7 Day Returns
0.9%
NasdaqCM:ICAD
-1.8%
US Healthcare Services
-0.3%
US Market
1 Year Returns
120.3%
NasdaqCM:ICAD
27.1%
US Healthcare Services
3.9%
US Market
ICAD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
iCAD (ICAD) 0.9% 10.2% 44.6% 120.3% 40% -19.9%
US Healthcare Services -1.8% 2.7% 19.6% 27.1% 64.2% 64.3%
US Market -0.3% 2.3% 2.3% 3.9% 36.7% 41.8%
1 Year Return vs Industry and Market
  • ICAD outperformed the Healthcare Services industry which returned 27.1% over the past year.
  • ICAD outperformed the Market in United States of America which returned 3.9% over the past year.
Price Volatility
ICAD
Industry
5yr Volatility vs Market

ICAD Value

 Is iCAD undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for iCAD. This is due to cash flow or dividend data being unavailable. The share price is $6.61.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for iCAD's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are iCAD's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:ICAD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.56
NasdaqCM:ICAD Share Price ** NasdaqCM (2019-07-19) in USD $6.61
United States of America Healthcare Services Industry PE Ratio Median Figure of 13 Publicly-Listed Healthcare Services Companies 57.35x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.92x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of iCAD.

NasdaqCM:ICAD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ICAD Share Price ÷ EPS (both in USD)

= 6.61 ÷ -0.56

-11.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iCAD is loss making, we can't compare its value to the US Healthcare Services industry average.
  • iCAD is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does iCAD's expected growth come at a high price?
Raw Data
NasdaqCM:ICAD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
106.3%per year
United States of America Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.33x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for iCAD, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on iCAD's assets?
Raw Data
NasdaqCM:ICAD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.26
NasdaqCM:ICAD Share Price * NasdaqCM (2019-07-19) in USD $6.61
United States of America Healthcare Services Industry PB Ratio Median Figure of 37 Publicly-Listed Healthcare Services Companies 5.13x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.8x
NasdaqCM:ICAD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ICAD Share Price ÷ Book Value per Share (both in USD)

= 6.61 ÷ 0.26

25.07x

* Primary Listing of iCAD.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • iCAD is overvalued based on assets compared to the US Healthcare Services industry average.
X
Value checks
We assess iCAD's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. iCAD has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ICAD Future Performance

 How is iCAD expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
106.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is iCAD expected to grow at an attractive rate?
  • iCAD's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • iCAD's earnings growth is expected to exceed the United States of America market average.
  • iCAD's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:ICAD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:ICAD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 106.3%
NasdaqCM:ICAD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 33.8%
United States of America Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 24.5%
United States of America Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 11.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:ICAD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:ICAD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 61 6 2
2020-12-31 44 0 3
2019-12-31 30 -6 3
NasdaqCM:ICAD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 26 -5 -9
2018-12-31 26 -4 -9
2018-09-30 27 -4 -10
2018-06-30 27 -6 -15
2018-03-31 28 -6 -17
2017-12-31 28 -7 -14
2017-09-30 27 -7 -13
2017-06-30 26 -6 -9
2017-03-31 27 -5 -8
2016-12-31 26 -5 -10
2016-09-30 27 -6 -9
2016-06-30 31 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • iCAD's earnings are expected to grow significantly at over 20% yearly.
  • iCAD's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:ICAD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from iCAD Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ICAD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.31 0.31 0.31 1.00
2020-12-31 0.01 0.05 -0.04 2.00
2019-12-31 -0.35 -0.29 -0.40 2.00
NasdaqCM:ICAD Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.56
2018-12-31 -0.54
2018-09-30 -0.60
2018-06-30 -0.94
2018-03-31 -1.04
2017-12-31 -0.87
2017-09-30 -0.82
2017-06-30 -0.56
2017-03-31 -0.50
2016-12-31 -0.63
2016-09-30 -0.58
2016-06-30 -0.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if iCAD will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess iCAD's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
iCAD has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ICAD Past Performance

  How has iCAD performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare iCAD's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • iCAD does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare iCAD's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare iCAD's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
iCAD's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from iCAD Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ICAD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 26.08 -9.45 17.71 8.23
2018-12-31 25.62 -9.02 17.81 9.45
2018-09-30 26.57 -9.91 15.83 9.70
2018-06-30 27.38 -15.48 16.48 9.92
2018-03-31 27.62 -17.08 17.67 10.09
2017-12-31 28.10 -14.26 18.38 9.33
2017-09-30 27.13 -13.34 19.13 9.74
2017-06-30 26.13 -9.08 18.71 9.85
2017-03-31 27.09 -8.02 18.67 9.82
2016-12-31 26.34 -10.10 17.85 9.52
2016-09-30 27.02 -9.19 18.05 9.38
2016-06-30 30.60 -6.91 18.76 9.11
2016-03-31 34.37 -33.12 19.52 9.18
2015-12-31 41.55 -32.45 21.19 9.16
2015-09-30 47.70 -30.14 21.62 8.83
2015-06-30 50.48 -29.47 22.53 8.82
2015-03-31 48.80 -2.68 21.77 8.55
2014-12-31 43.92 -1.01 20.51 8.16
2014-09-30 39.19 -5.32 19.57 7.75
2014-06-30 35.00 -6.19 17.66 7.29
2014-03-31 33.12 -7.07 16.86 7.04
2013-12-31 33.07 -7.61 16.69 7.04
2013-09-30 31.36 -5.90 16.60 6.86
2013-06-30 31.37 -6.78 17.39 7.20
2013-03-31 29.73 -7.84 17.54 7.42
2012-12-31 28.28 -9.37 16.94 7.03
2012-09-30 27.07 -8.90 18.89 8.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if iCAD has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if iCAD has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if iCAD improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess iCAD's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
iCAD has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ICAD Health

 How is iCAD's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up iCAD's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • iCAD is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • iCAD's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of iCAD's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from iCAD Company Filings, last reported 3 months ago.

NasdaqCM:ICAD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 4.57 15.44 11.32
2018-12-31 6.90 13.08 12.19
2018-09-30 9.77 6.06 6.81
2018-06-30 10.79 6.04 7.79
2018-03-31 11.44 6.00 8.66
2017-12-31 14.28 5.94 9.39
2017-09-30 18.00 5.93 11.26
2017-06-30 24.43 0.00 7.68
2017-03-31 25.53 0.00 9.54
2016-12-31 25.04 0.00 8.59
2016-09-30 27.73 0.00 10.48
2016-06-30 29.79 0.00 11.47
2016-03-31 30.83 0.00 12.87
2015-12-31 32.75 0.00 15.28
2015-09-30 34.60 0.00 17.54
2015-06-30 34.44 0.00 18.21
2015-03-31 61.60 0.00 20.27
2014-12-31 62.78 9.35 32.22
2014-09-30 62.43 12.82 33.44
2014-06-30 52.93 12.50 34.85
2014-03-31 49.94 15.66 38.40
2013-12-31 21.38 15.52 11.88
2013-09-30 25.35 15.30 10.21
2013-06-30 25.64 15.17 12.91
2013-03-31 27.24 15.00 12.67
2012-12-31 27.67 14.85 13.95
2012-09-30 30.10 14.60 13.79
  • iCAD's level of debt (338.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (31.9% vs 338.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • iCAD has sufficient cash runway for 2.1 years based on current free cash flow.
  • iCAD has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -1.4% each year.
X
Financial health checks
We assess iCAD's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. iCAD has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ICAD Dividends

 What is iCAD's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from iCAD dividends.
If you bought $2,000 of iCAD shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate iCAD's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate iCAD's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:ICAD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 16 Stocks 1.1%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:ICAD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as iCAD has not reported any payouts.
  • Unable to verify if iCAD's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of iCAD's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as iCAD has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess iCAD's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can iCAD afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. iCAD has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ICAD Management

 What is the CEO of iCAD's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Klein
COMPENSATION $1,633,507
AGE 65
TENURE AS CEO 0.7 years
CEO Bio

Mr. Michael S. Klein, also known as Mike, has been Executive Chairman of iCAD, Inc. since November 9, 2018. Mr. Mike is Chief Executive Officer of iCAD, Inc. since December 12, 2018. Mr. Mike was an Interim CEO of iCAD, Inc. since November 9, 2018 until December 12, 2018. He was a Director of iCAD, Inc. since September 26, 2018. Mr. Klein served as the Chief Executive Officer at SonaCare Medical, LLC since January 2012. He has served as the Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services, since December 2014. Prior to that, he was the Chief Executive Officer at US HIFU, LLC (f/k/a SonaCare Medical, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies, from December 2011 to November 2014. Mr. Klein served as the President of Radiation Oncology Division at CIVCO Medical Instruments Co., Inc. since May 2011. He served as the Chief Executive Officer and President of Xoft Inc., from December 2004 to December 2010. He served as the Chairman of the Board, Chief Executive Officer and President of R2 Technology, Inc. from May 2000 to 2004. From 1997 to 2000, he served as Vice President and General Manager of the Oncology Systems Group at Varian Medical Systems, Inc. and served as its Senior Vice President. From 1990 to 1997, he served in a series of senior management positions at Becton Dickinson and Company, including as Vice President of Sales and Marketing for BD Medical's North American Sales & Marketing Group. He held various sales, marketing, planning and business development positions with several major corporations. He serves as a Director of Sanarus Medical, Inc. He served as a Director of iCAD, Inc. since 2010 until May 15, 2014. He served as a Director of Xoft Inc., since December 2004. He served as a Director for SonaCare Medical, LLC since January 2012. He served as a Director of R2 Technology Inc. In 2008, Mr. Klein received the R&D Magazine Top 100 Award on behalf of Xoft, where honors were awarded for the 100 most technologically significant new products of 2008. He received a similar award in 2008 from Frost & Sullivan. Mr. Klein received an MBA from the New York Institute of Technology and a B.A. degree in history and education from the State University of New York, Albany. He completed his post-graduate Executive Education Studies at Harvard University and Babson College.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the iCAD management team in years:

0.5
Average Tenure
56
Average Age
  • The average tenure for the iCAD management team is less than 2 years, this suggests a new team.
Management Team

Mike Klein

TITLE
Executive Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
0.7 yrs

Stacey Stevens

TITLE
President
COMPENSATION
$433K
AGE
51
TENURE
0.3 yrs

Richard Areglado

TITLE
Chief Financial Officer
COMPENSATION
$285K
AGE
55
TENURE
0.6 yrs

Jonathan Go

TITLE
Chief Technology Officer
COMPENSATION
$501K
AGE
56
TENURE
0.5 yrs

Annette Heroux

TITLE
Vice President of Administration
COMPENSATION
$178K
AGE
62
Board of Directors Tenure

Average tenure and age of the iCAD board of directors in years:

0.8
Average Tenure
55.5
Average Age
  • The average tenure for the iCAD board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mike Klein

TITLE
Executive Chairman & CEO
COMPENSATION
$2M
AGE
65
TENURE
0.7 yrs

Andy Sassine

TITLE
Director
COMPENSATION
$53K
AGE
55
TENURE
3.6 yrs

Rakesh Patel

TITLE
Director
COMPENSATION
$12K
AGE
45
TENURE
0.8 yrs

Susan Wood

TITLE
Director
COMPENSATION
$13K
AGE
56
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess iCAD's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. iCAD has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ICAD News

Simply Wall St News

Does iCAD, Inc. (NASDAQ:ICAD) Have A High Beta?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … This is reasonably close to the market beta of 1, so the stock has in the past displayed similar levels of volatility to the overall market. … What this means for you: It is probable that there is a link between the share price of iCAD and the broader market, since it has a beta value quite close to one.

Simply Wall St -

Does iCAD's (NASDAQ:ICAD) Share Price Gain of 87% Match Its Business Performance?

The longer term returns have not been as good, with the stock price only 12% higher than it was three years ago. … View our latest analysis for iCAD Because iCAD is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … We can correlate the share price rise with revenue or profit growth, but it seems the market had previously expected weaker results, and sentiment around the stock is improving.

Simply Wall St -

What Kind Of Shareholder Appears On The iCAD, Inc.'s (NASDAQ:ICAD) Shareholder Register?

Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … See our latest analysis for iCAD NasdaqCM:ICAD Ownership Summary, May 24th 2019 What Does The Institutional Ownership Tell Us About iCAD? … General Public Ownership The general public -- mostly retail investors -- own 61% of iCAD.

Simply Wall St -

iCAD, Inc.'s (NASDAQ:ICAD) Profit Outlook

provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. … Below I will provide a high-level summary of the industry analysts’ expectations for ICAD … See our latest analysis for iCAD

Simply Wall St -

Does iCAD, Inc. (NASDAQ:ICAD) Have A High Beta?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Kind Of Shareholder Appears On The iCAD, Inc.'s (NASDAQ:ICAD) Shareholder Register?

Generally speaking, as a company grows, institutions will increase their ownership. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … We can zoom in on the different ownership groups, to learn more about ICAD

Simply Wall St -

iCAD Inc's (NASDAQ:ICAD) Profit Outlook

With the latest financial year loss of -US$14.3m and a trailing-twelve month of -US$9.9m, the US$47m market-cap alleviates its loss by moving closer towards its target of breakeven. … I’ve put together a brief outline of industry analyst expectations for ICAD, its year of breakeven and its implied growth rate … ICAD is bordering on breakeven, according to Healthcare Services analysts.

Simply Wall St -

Does iCAD Inc's (NASDAQ:ICAD) CEO Salary Reflect Performance?

How Does Ken Ferry's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m. … Thus we can conclude that Ken Ferry receives more in total compensation than the median of a group of companies in the same market, and of similar size to iCAD Inc

Simply Wall St -

Who Are The Major Shareholders Of iCAD Inc (NASDAQ:ICAD)?

The big shareholder groups in iCAD Inc (NASDAQ:ICAD) have power over the company. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … We can zoom in on the different ownership groups, to learn more about ICAD

Simply Wall St -

What Investors Should Know About iCAD Inc's (NASDAQ:ICAD) Financial Strength

iCAD Inc (NASDAQ:ICAD) is a small-cap stock with a market capitalization of US$49.82m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

ICAD Company Info

Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer’s network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Details
Name: iCAD, Inc.
ICAD
Exchange: NasdaqCM
Founded: 1984
$127,321,370
19,261,932
Website: http://www.icadmed.com
Address: iCAD, Inc.
98 Spit Brook Road,
Suite 100,
Nashua,
New Hampshire, 03062,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ICAD Common Stock Nasdaq Capital Market US USD 13. Dec 1984
DB HWT1 Common Stock Deutsche Boerse AG DE EUR 13. Dec 1984
Number of employees
Current staff
Staff numbers
96
iCAD employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 23:38
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/12
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.